OECD Policy Responses to Coronavirus (COVID-19)
This series compiles data, analysis and recommendations on a range of topics to address the health, economic and societal crisis, facilitate co-ordination, and contribute to the necessary global action when confronting this enormous collective challenge. Bringing together policy responses spanning a large range of topics, from health to education and taxes, it provides guidance on the short-term measures in affected sectors and a specific focus on the vulnerable sectors of society and the economy. The content also aims to provide analysis on the longer-term consequences and impacts, steering the way towards a strong, resilient, green and inclusive recovery with co-ordinated policy responses across countries.
Also available in: French, German, Portuguese, Spanish, Japanese
- ISSN: 27080676 (online)
- https://doi.org/10.1787/5b0fd8cd-en
Greater harmonisation of clinical trial regulations would help the fight against COVID-19
This brief discusses the existing obstacles in developing international clinical trials that are critical to fight the COVID-19 pandemic. It provides information on relevant adaptations of regulatory requirements for clinical trials, intended to accelerate the processes, and highlights the need to harmonise further these regulations between national regulatory authorities. To this end, this brief describes the existing OECD Recommendation on the Governance of Clinical Trials issued in 2012 and how its implementation could greatly facilitate and streamline the registration and conduct of international clinical trials.
Also available in: French
- Click to access:
-
Click to access in HTMLWEB
-
Click to Read online and shareREAD